I. Introduction: A New Era for Chinese Vaccines
China has long been a manufacturer of vaccines for its domestic market. In recent years, however, Chinese vaccine developers have set their sights on the global market — and WHO prequalification (PQ) is the key that unlocks it.
WHO prequalification is a rigorous assessment process that ensures vaccines meet international standards of quality, safety, and efficacy. It is a pre-requisite for vaccines to be procured by UN agencies (including UNICEF, PAHO, and GAVI) for global public health programs.
In 2024–2026, Chinese vaccines achieved a series of WHO PQ milestones — demonstrating that China's vaccine industry has reached global standards and is ready to contribute to global immunization efforts.
• WALRINVAX® (HPV) – WHO prequalified in 2024, expanded to Tanzania in 2026
• 9-valent HPV vaccine – China's first 9-valent HPV vaccine submitted for WHO PQ in June 2026
• Chinese vaccines are now global public health tools, not just domestic products
II. WALRINVAX® – WHO Prequalified HPV Vaccine from China
WALRINVAX® is a bivalent HPV vaccine developed by Walvax Biotechnology (沃森生物). It received WHO prequalification in August 2024 — making it one of the first Chinese HPV vaccines to achieve this global recognition.
Key Details
| Aspect | Details |
|---|---|
| Product | WALRINVAX® (bivalent HPV vaccine) |
| Developer | Walvax Biotechnology (沃森生物) |
| WHO PQ Status | Prequalified (August 2024) |
| 2026 Milestone | Marketing authorization in Tanzania (July 2026) |
2026 Expansion: Tanzania Approval
In July 2026, Walvax announced that WALRINVAX® received marketing authorization from the Tanzania Medicines and Medical Devices Authority (TMDA). This marks the vaccine's entry into the African market — a critical step in expanding access to HPV vaccination in low- and middle-income countries.
Significance: Tanzania's approval demonstrates that WHO prequalification serves as a regulatory shortcut — many countries accept WHO PQ as sufficient evidence for national marketing authorization, accelerating the global distribution of Chinese vaccines.
III. China's First 9-Valent HPV Vaccine Submitted for WHO PQ
On June 1, 2026, Wantai Biologics (万泰生物) submitted its 9-valent HPV vaccine — China's first 9-valent HPV vaccine and the world's second 9-valent HPV vaccine (after Merck's Gardasil 9) — for WHO prequalification.
Key Details
| Aspect | Details |
|---|---|
| Product | 9-valent HPV vaccine (China's first) |
| Developer | Wantai Biologics (万泰生物) |
| WHO PQ Submission | June 1, 2026 |
| Global Significance | World's second 9-valent HPV vaccine submitted for WHO PQ |
Why This Matters
- Global supply of HPV vaccine has been constrained for years, limiting access in developing countries. A second WHO-prequalified 9-valent HPV vaccine would double the global supply and reduce costs.
- Competitive pricing: Chinese HPV vaccines are priced significantly lower than Merck's Gardasil 9, making them more accessible to low- and middle-income countries.
- WHO's Cervical Cancer Elimination Strategy: The WHO has set a target to eliminate cervical cancer by 2030, requiring 90% HPV vaccination coverage. Chinese HPV vaccines are critical to achieving this goal.
IV. Other Chinese Vaccines with Global Recognition
Beyond HPV vaccines, Chinese vaccine developers have achieved WHO PQ for several other vaccines:
| Vaccine | Developer | WHO PQ Status | Indication |
|---|---|---|---|
| COVID-19 vaccines | Sinovac, Sinopharm, CanSino | Emergency Use Listing (2020–2022) | COVID-19 |
| Influenza vaccine | Sinovac, others | Prequalified (various dates) | Seasonal influenza |
| Polio vaccine | Multiple manufacturers | Prequalified | Poliomyelitis |
| Hepatitis B vaccine | Multiple manufacturers | Prequalified | Hepatitis B |
V. The Significance of WHO Prequalification
Access to Global Public Markets
WHO prequalification is the gateway to global public procurement. UN agencies, GAVI, and national governments rely on WHO PQ to select vaccines for their immunization programs. Without WHO PQ, vaccines are effectively excluded from most global public health procurement.
Quality Assurance
The WHO PQ process is rigorous and independent. It includes:
- Manufacturing site inspections to ensure GMP compliance
- Batch testing to confirm potency and safety
- Clinical data review to verify efficacy
- Ongoing monitoring of post-market safety
WHO PQ status is a stamp of approval that the vaccine meets international standards.
Cost Reduction
Chinese vaccines are generally priced lower than their Western counterparts. WHO PQ enables these lower-cost vaccines to compete in global tenders, reducing the cost of immunization programs in developing countries.
Global Health Impact
Chinese vaccines are already making a significant impact on global health. The COVID-19 pandemic demonstrated China's vaccine manufacturing capacity and willingness to supply global markets. HPV vaccines are now following the same trajectory.
VI. What This Means for International Patients
Access to Affordable Vaccines
International patients — particularly those in developing countries — benefit from the availability of WHO-prequalified Chinese vaccines at lower prices. This expands access to life-saving vaccines like HPV vaccine.
Confidence in Quality
WHO PQ provides independent validation of vaccine quality. International patients can have confidence that Chinese vaccines with WHO PQ meet the same standards as vaccines from Western manufacturers.
Choice and Competition
The entry of Chinese vaccines into the global market increases competition, which benefits patients through lower prices and improved supply reliability.
VII. Future Outlook
China's vaccine industry is poised for continued global expansion:
- 9-valent HPV vaccine is expected to receive WHO PQ in 2027–2028, significantly expanding global HPV vaccine supply.
- mRNA vaccine platforms developed during COVID-19 are being repurposed for other infectious diseases.
- Combination vaccines (e.g., HPV + COVID-19, HPV + other antigens) are in development.
- Expansion of manufacturing capacity to meet global demand.
VIII. Conclusion: China's Vaccines Go Global
The WHO prequalification of Chinese vaccines — from HPV vaccines to COVID-19 vaccines — marks a new era for China's vaccine industry. Chinese vaccines are no longer just for domestic use; they are now global public health tools reaching patients in countries around the world.
With the 9-valent HPV vaccine now in the WHO PQ pipeline and WALRINVAX® expanding into Africa, China is poised to become a leading global supplier of vaccines for the world's most pressing public health needs.
China's vaccines have gone global — and the world is healthier for it.